Immune mediated neuropathy following checkpoint immunotherapy
- 1 November 2017
- journal article
- case report
- Published by Elsevier BV in Journal of Clinical Neuroscience
- Vol. 45, 14-17
- https://doi.org/10.1016/j.jocn.2017.07.014
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Breathing new life into immunotherapy: review of melanoma, lung and kidney cancerNature Reviews Clinical Oncology, 2013
- Multifocal radiculoneuropathy during ipilimumab treatment of melanomaMuscle & Nerve, 2013
- Management of Immune-Related Adverse Events and Kinetics of Response With IpilimumabJournal of Clinical Oncology, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin TherapyJournal of Clinical Oncology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4Journal of Clinical Oncology, 2006